SILAC-based proteomic profiling of the ...
Type de document :
Article dans une revue scientifique
PMID :
URL permanente :
Titre :
SILAC-based proteomic profiling of the human MDA-MB-231 metastatic breast cancer cell line in response to the two antitumoral lactoferrin isoforms: the secreted lactoferrin and the intracellular delta-lactoferrin
Auteur(s) :
Hoedt, Esthelle [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 [UGSF]
Chaoui, Karima [Auteur]
Institut de pharmacologie et de biologie structurale [IPBS]
Huvent, Isabelle [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle UMR 8576 [UGSF]
Mariller, Christophe [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle UMR 8576 [UGSF]
Monsarrat, Bernard [Auteur]
Institut de pharmacologie et de biologie structurale [IPBS]
Burlet-Schiltz, Odile [Auteur]
Institut de pharmacologie et de biologie structurale [IPBS]
Pierce, Annick [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 [UGSF]
Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 [UGSF]
Chaoui, Karima [Auteur]
Institut de pharmacologie et de biologie structurale [IPBS]
Huvent, Isabelle [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle UMR 8576 [UGSF]
Mariller, Christophe [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle UMR 8576 [UGSF]
Monsarrat, Bernard [Auteur]
Institut de pharmacologie et de biologie structurale [IPBS]
Burlet-Schiltz, Odile [Auteur]
Institut de pharmacologie et de biologie structurale [IPBS]
Pierce, Annick [Auteur]
Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 [UGSF]
Titre de la revue :
PLoS One
Nom court de la revue :
PLoS ONE
Numéro :
9
Pagination :
e104563
Date de publication :
2014-08
ISSN :
1932-6203
Mot(s)-clé(s) en anglais :
Promoter Regions, Genetic
Reproducibility of Results
Alternative Splicing
Response Elements
Humans
Gene Expression Regulation, Neoplastic
Proteome
Recombinant Proteins
Breast Neoplasms
Lactoferrin
Neoplasm Metastasis
Protein Isoforms
Proteomics
Cell Line, Tumor
Protein Binding
Isotope Labeling
Female
Transcription Factors
Ubiquitin-Conjugating Enzymes
Selenoproteins
Transcription Factors, TFII
Reproducibility of Results
Alternative Splicing
Response Elements
Humans
Gene Expression Regulation, Neoplastic
Proteome
Recombinant Proteins
Breast Neoplasms
Lactoferrin
Neoplasm Metastasis
Protein Isoforms
Proteomics
Cell Line, Tumor
Protein Binding
Isotope Labeling
Female
Transcription Factors
Ubiquitin-Conjugating Enzymes
Selenoproteins
Transcription Factors, TFII
Discipline(s) HAL :
Chimie/Chimie théorique et/ou physique
Résumé en anglais : [en]
BACKGROUND: Lactoferrins exhibit antitumoral activities either as a secretory lactoferrin or an intracellular delta-lactoferrin isoform. These activities involve processes such as regulation of the cell cycle and apoptosis. ...
Lire la suite >BACKGROUND: Lactoferrins exhibit antitumoral activities either as a secretory lactoferrin or an intracellular delta-lactoferrin isoform. These activities involve processes such as regulation of the cell cycle and apoptosis. While lactoferrin has been shown to exert its function by activating different transduction pathways, delta-lactoferrin has been proven to act as a transcription factor. Like many tumor suppressors, these two proteins are under-expressed in several types of cancer, particularly in breast cancer. METHODOLOGY/PRINCIPAL FINDINGS: In order to compare the differential effects of the re-introduction of lactoferrin isoforms in breast cancer cells we chose the cancerous mammary gland MDA-MB-231 cell line as a model. We produced a cell line stably expressing delta-lactoferrin. We also treated these cells with fresh purified human breast lactoferrin. We performed two quantitative proteomic studies in parallel using SILAC coupled to mass spectrometry in order to compare the effects of different doses of the two lactoferrin isoforms. The proteome of untreated, delta-lactoferrin expressing and human lactoferrin treated MDA-MB-231 cells were compared. Overall, around 5300 proteins were identified and quantified using the in-house developed MFPaQ software. Among these, expression was increased by 1.5-fold or more for around 300 proteins in delta-lactoferrin expressing cells and 190 proteins in lactoferrin treated cells. At the same time, about 200 and 40 proteins were found to be downregulated (0-0.7-fold) in response to delta-lactoferrin and lactoferrin, respectively. CONCLUSIONS/SIGNIFICANCE: Re-introduction of delta-lactoferrin and lactoferrin expression in MDA-MB-231 mainly leads to modifications of protein profiles involved in processes such as proliferation, apoptosis, oxidative stress, the ubiquitin pathway, translation and mRNA quality control. Moreover, this study identified new target genes of delta-lactoferrin transcriptional activity such as SelH, GTF2F2 and UBE2E1.Lire moins >
Lire la suite >BACKGROUND: Lactoferrins exhibit antitumoral activities either as a secretory lactoferrin or an intracellular delta-lactoferrin isoform. These activities involve processes such as regulation of the cell cycle and apoptosis. While lactoferrin has been shown to exert its function by activating different transduction pathways, delta-lactoferrin has been proven to act as a transcription factor. Like many tumor suppressors, these two proteins are under-expressed in several types of cancer, particularly in breast cancer. METHODOLOGY/PRINCIPAL FINDINGS: In order to compare the differential effects of the re-introduction of lactoferrin isoforms in breast cancer cells we chose the cancerous mammary gland MDA-MB-231 cell line as a model. We produced a cell line stably expressing delta-lactoferrin. We also treated these cells with fresh purified human breast lactoferrin. We performed two quantitative proteomic studies in parallel using SILAC coupled to mass spectrometry in order to compare the effects of different doses of the two lactoferrin isoforms. The proteome of untreated, delta-lactoferrin expressing and human lactoferrin treated MDA-MB-231 cells were compared. Overall, around 5300 proteins were identified and quantified using the in-house developed MFPaQ software. Among these, expression was increased by 1.5-fold or more for around 300 proteins in delta-lactoferrin expressing cells and 190 proteins in lactoferrin treated cells. At the same time, about 200 and 40 proteins were found to be downregulated (0-0.7-fold) in response to delta-lactoferrin and lactoferrin, respectively. CONCLUSIONS/SIGNIFICANCE: Re-introduction of delta-lactoferrin and lactoferrin expression in MDA-MB-231 mainly leads to modifications of protein profiles involved in processes such as proliferation, apoptosis, oxidative stress, the ubiquitin pathway, translation and mRNA quality control. Moreover, this study identified new target genes of delta-lactoferrin transcriptional activity such as SelH, GTF2F2 and UBE2E1.Lire moins >
Langue :
Anglais
Audience :
Non spécifiée
Projet Européen :
Établissement(s) :
CNRS
Université de Lille
Université de Lille
Équipe(s) de recherche :
O-GlcNAcylation, signalisation cellulaire et cycle cellulaire
Date de dépôt :
2020-02-12T15:11:49Z
2021-03-18T10:52:06Z
2021-03-18T10:52:06Z
Fichiers
- pone.0104563.pdf
- Version éditeur
- Accès libre
- Accéder au document